SANTA CLARA, Calif., March 10, 2025--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications ...

Agilent (A) Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early ...

Researchers use antibody-based detection methods such as immunohistochemistry (IHC) to explore the spatial distribution and levels of PD-L1 on both tumour and immune cells. There are several ...

The expression of PD-L1 and mismatch repair enzymes was evaluated in cases with available immunohistochemistry (IHC) data. These findings reinforce therapeutic efforts to target IDH signaling in ...

Many cancer patients who score negatively on a PD-L1 IHC still respond anti-PD-1 ICIs. Researchers are looking at alternatives to PCR and conventional IHC. Phenoptics mIF is one. Scientists have ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...

Deep Bio, a pioneer in AI-powered digital pathology, will present new research at the American Association for Cancer ...

SANTA CLARA, Calif., March 10, 2025--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals ...